These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 10288911)

  • 1. Genetic advance at a price.
    Chappie J
    Health Serv J; 1988 Aug; 98(5115):970-1. PubMed ID: 10288911
    [No Abstract]   [Full Text] [Related]  

  • 2. State-sponsored genetic services in Maryland.
    Panny SR; Bernhardt BA
    Md Med J; 1989 Nov; 38(11):925-32. PubMed ID: 2511391
    [No Abstract]   [Full Text] [Related]  

  • 3. msJAMA. Genomics in medicine and public health: role of cost-effectiveness analysis.
    Goldie SJ; Levin AR
    JAMA; 2001 Oct; 286(13):1637-8. PubMed ID: 11585493
    [No Abstract]   [Full Text] [Related]  

  • 4. Economics of genetics from a health commissioning point of view.
    Turner RD
    Dis Markers; 1999 Oct; 15(1-3):175-6. PubMed ID: 10595274
    [No Abstract]   [Full Text] [Related]  

  • 5. A scientific basis for cost-benefit analysis of genetics services.
    Modell B; Kuliev AM
    Trends Genet; 1993 Feb; 9(2):46-52. PubMed ID: 8456501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should insurance pay for preventive services suggested by genetics?
    Lawrence J
    Manag Care; 1997 Jan; 6(1):42-6. PubMed ID: 10164532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can we really afford to spend NHS cash on genetic testing for cancer?
    Nurs Times; 2002 Oct 8-14; 98(41):3. PubMed ID: 12430394
    [No Abstract]   [Full Text] [Related]  

  • 8. Is there a cure for cancer ads?
    Kahn J
    Fortune; 2003 Mar; 147(4):46. PubMed ID: 12633023
    [No Abstract]   [Full Text] [Related]  

  • 9. Roche chases stake in medical sequencing.
    Hayden EC
    Nature; 2012 Apr; 484(7393):152. PubMed ID: 22498604
    [No Abstract]   [Full Text] [Related]  

  • 10. Registers for the prevention of genetic disease.
    Br Med J; 1979 Jan; 1(6158):215-6. PubMed ID: 421038
    [No Abstract]   [Full Text] [Related]  

  • 11. General session: cost-effectiveness of screening for genetic predisposition to diseases of adult onset.
    Rotter JI
    J Insur Med; 1993; Suppl B():216-28. PubMed ID: 10146357
    [No Abstract]   [Full Text] [Related]  

  • 12. Health at what price?
    Roberts H; Robinson R
    Health Serv J; 1989 Dec; 99(5180):1511. PubMed ID: 10296353
    [No Abstract]   [Full Text] [Related]  

  • 13. Genetic tests and staff are cut to save money.
    Cole A
    BMJ; 2006 Dec; 333(7581):1238. PubMed ID: 17170407
    [No Abstract]   [Full Text] [Related]  

  • 14. Genetic discrimination by insurers: legal protections needed from abuse of biotechnology.
    Morelli TE
    Healthspan; 1992 Sep; 9(8):8-11. PubMed ID: 10122055
    [No Abstract]   [Full Text] [Related]  

  • 15. Myriad stands alone.
    Sherkow JS; Scott C
    Nat Biotechnol; 2014 Jul; 32(7):620. PubMed ID: 25004225
    [No Abstract]   [Full Text] [Related]  

  • 16. Primary care for patients at genetic risk.
    Harris R; Harris HJ
    BMJ; 1995 Sep; 311(7005):579-80. PubMed ID: 7663241
    [No Abstract]   [Full Text] [Related]  

  • 17. What price sick beds?
    Webber J
    Health Serv J; 1988 Oct; 98(5122):1204. PubMed ID: 10290088
    [No Abstract]   [Full Text] [Related]  

  • 18. Screening for genetic diseases: principles and practice.
    Jolly RD; Dodds WJ; Ruth GR; Trauner DB
    Adv Vet Sci Comp Med; 1981; 25():245-76. PubMed ID: 7034500
    [No Abstract]   [Full Text] [Related]  

  • 19. [The real « personal genome » ?].
    Jordan B
    Med Sci (Paris); 2011 May; 27(5):553-6. PubMed ID: 21609679
    [No Abstract]   [Full Text] [Related]  

  • 20. Illumina claims $1,000 genome win.
    Sheridan C
    Nat Biotechnol; 2014 Feb; 32(2):115. PubMed ID: 24509738
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.